Patent Extension Policy for Paediatric Indications

By Nelson, Richard E.; McAdam-Marx, Carrie et al. | Applied Health Economics and Health Policy, May 2011 | Go to article overview

Patent Extension Policy for Paediatric Indications


Nelson, Richard E., McAdam-Marx, Carrie, Evans, Megan L., Ward, Robert, Campbell, Benjamin, Brixner, Diana, Lafleur, Joanne, Applied Health Economics and Health Policy


Background

Children often experience the same conditions as adults, many of which can be treated with pharmaceuticals. Yet, it was estimated in 1999 that <25% of all drugs marketed in the US had a paediatric indication, meaning that they lacked data and product labelling on safety, efficacy and dosing in children.[1] Because of this, physicians are often confronted with the dilemma of whether to prescribe a medication for a child 'off label' and possibly put the child at risk or to deny the child the potential benefits of off-label therapy.

In efforts to remedy this situation, the Food and Drug Administration Modernization Act of 1997 (FDAMA)[2] included The Pediatric Exclusivity Provision, Section 505A, that provided a 6-month market exclusivity extension as an incentive for pharmaceutical manufacturers to conduct clinical trials in children as requested by the FDA. This provision was renewed in 2002 as the Best Pharmaceuticals for Children Act (BPCA)[3] and again as the Pediatric Research Equity Act of 2007.[4] Since the FDAMA was passed, 355 product labelling changes specific to children have been made.[5]

By design, paediatric exclusivity generates a cost to society by delaying the entry of less expensive generic versions of the drug into the market. This extra 6 months of unchallenged revenue provides an incentive for manufacturers to generate paediatric drug data when these incentives are not provided by the market. In a 2001 Report to Congress, the FDA estimated that the cost to consumers over the next 20 years would be $US13.9 billion ($US695 million per year).[6] Critics contend that these costs reflect a disproportionate benefit to manufacturers, whose additional profits from having 6 additional months of market exclusivity are far greater than the costs of conducting the trials.[7] Improvements in children's healthcare by more accurate dosing and reductions in adverse drug effects have been postulated but have been much harder to measure. Furthermore, many medications that are used in children are multisource products (i.e. they are available generically) and therefore do not qualify for the Pediatric Exclusivity Provision. Because of this, there is little incentive for manufacturers to study these drugs in children. Instead, the BPCA established funding for a National Institutes of Health programme to contract for paediatric studies in off-patent products.[3]

In this paper, we estimate the cost impact of the 6-month exclusivity extension policy on the Utah Medicaid drug programme. To do this, we selected three classes of drugs: selective serotonin reuptake inhibitors (SSRIs), HMG-CoA reductase inhibitors (statins) and ACE inhibitors (ACE-Is). These classes were selected for evaluation as they have the most representation on the list of products granted paediatric exclusivity and are top-selling drug classes in the Medicaid programme. SSRIs are commonly used in both adult and paediatric patients, and statins and ACE-Is are regularly used in adults but rarely used in children. Two drug classes that are often used in children, amphetamines/stimulants and sodium channel blocker anticonvulsants, were identified but not included in the analysis because of many factors that precluded our ability to accurately conduct a cost analysis. In the case of amphetamines/stimulants, methylphenidate and Adderall® were granted patent extensions through the Pediatric Exclusivity Provision, but neither could be included in the analysis. The patent for methylphenidate was overly complex because of various dosage forms and because the patent extension applies to the drug moiety in all dosage forms. Adderall® could not be included in the analysis because of product line extensions (e.g. Adderall XR® ) that captured much of the market share prior to the original product's patient expiration, leading to little generic shift. In the case of sodium channel blocker anticonvulsants, our analysis could not be conducted on the drug lamotrigine because of a legal battle that caused the first generic exclusivity to last 3 years rather than the typical 6 months. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Patent Extension Policy for Paediatric Indications
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Author Advanced search

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.